News & Updates

Show Multimedia Only

Patients with MASLD face heightened diabetes risk

14 Jul 2026 by

Metabolic dysfunction-associated steatotic liver disease (MASLD) carries an increased risk of type 2 diabetes (T2D), with the risk increase disproportionately higher for individuals with earlier-onset MASLD, as shown in a study.

Patients with MASLD face heightened diabetes risk

14 Jul 2026

AI pathology model assists in liver cancer diagnosis

09 Jul 2026

A confidence-based artificial intelligence (AI) biomarker demonstrates clinical utility in the diagnosis of liver cancer, according to a real-world study.

AI pathology model assists in liver cancer diagnosis

09 Jul 2026

Hepatic steatosis increases non-calcified plaque burden

08 Jul 2026

Hepatic steatosis may raise the risk of major adverse cardiovascular events through increased non-calcified plaque burden, according to a study.

Hepatic steatosis increases non-calcified plaque burden

08 Jul 2026

MELD best predictor of outcomes in alcohol-related liver disease: study

07 Jul 2026

A recent study describes the natural history of alcohol-associated liver disease (ALD) and the risks of outcomes based on the model for end-stage liver disease (MELD) score across the ALD spectrum.

MELD best predictor of outcomes in alcohol-related liver disease: study

07 Jul 2026

Beta-blocker therapy confers survival benefit in viral hepatitis-related cirrhosis

07 Jul 2026

Among patients with viral hepatitis-related cirrhosis who sustained non-bleeding decompensating events, the use of non-selective beta blockers is associated with lower mortality, as shown in a study.

Beta-blocker therapy confers survival benefit in viral hepatitis-related cirrhosis

07 Jul 2026

Switching to entecavir reduces relapse, flare in HBeAg-negative patients

06 Jul 2026

In hepatitis B e antigen-negative (HBeAg) patients, the last antiviral agent used prior to end of therapy (EOT) appears predictive of the timing of clinical relapse, according to a study. An entecavir-switching strategy may prevent relapse and reduce hepatitis flare and its severity within 24 weeks after EOT.

Switching to entecavir reduces relapse, flare in HBeAg-negative patients

06 Jul 2026

Norucholic acid, with or without UDCA, prevents PSC progression

01 Jul 2026 by

Patients with primary sclerosing cholangitis (PSC) who received norucholic acid (NCA), with or without ursodeoxycholic acid (UDCA) background therapy, were more likely to achieve histological and biochemical improvements than those receiving placebo, according to the subgroup analysis of the NUC-5 trial presented at EASL 2026.

Norucholic acid, with or without UDCA, prevents PSC progression

01 Jul 2026

Liver transplant recipients at increased risk of coronary atherosclerosis

22 Jun 2026

The prevalence and severity of coronary atherosclerosis are significantly higher among recipients of liver transplant than the general population, a study has shown.